- Home
- LRMR vs DERM Comparison
LRMR vs DERM Comparison
Compare LRMR & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LRMR | DERM |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.1M | 210.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LRMR | DERM |
|---|---|---|
| Price | $3.72 | $8.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $16.71 | $12.67 |
| AVG Volume (30 Days) | ★ 1.2M | 141.2K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $59,399,000.00 |
| Revenue This Year | N/A | $17.48 |
| Revenue Next Year | N/A | $55.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.82 |
| 52 Week Low | $1.61 | $3.86 |
| 52 Week High | $5.37 | $9.56 |
Technical Indicators
Market Signals| Indicator | LRMR | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 56.32 | 52.14 |
| Support Level | $3.05 | $8.02 |
| Resistance Level | $3.72 | $9.56 |
| Average True Range (ATR) | 0.23 | 0.61 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 94.37 | 47.82 |
Price Performance
Historical ComparisonAbout LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.